Ivermectin

Dermatologic Clinics

Volumn 21, Issue 2, 2003, Pages 277-282

  Elgart, George W ^a   Meinking, Terri L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; BENZYL BENZOATE; CORTICOSTEROID; DIETHYLCARBAMAZINE; IVERMECTIN; LINDANE; PERMETHRIN;

DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FILARIASIS; FLUSHING; HUMAN; LARVA MIGRANS; MYIASIS; NAUSEA; ONCHOCERCIASIS; PEDICULOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ROSACEA; SCABIES; STRONGYLOIDIASIS; TABLET; TACHYCARDIA;

EID: 0038071504     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00095-5     Document Type: Review

References (52)

1. Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother 1994;34:195-203.
2. Overview of Philanthropy. The story of mectizan, Merck. Available: http://www.merck.com/overview/philanthropy/mectizan/home.html. Accessed January 5, 2002.
3. Stromectol (ivermectin). Package insert, Merck & Co. West Point, PA. 1996.
4. Burkhart CN. Ivermectin: an assessment of its pharmacology, microbiology and safety. Vet Hum Toxicol 2000;42:30-5.
5. Kane NS, Hirschberg B, Qian S, et al. Drug-resistant Drosophilia indicate glutamate-gated chloride channels are targets for the antiparasitics nodulispordic acid and ivermectin. Proc Natl Acad Sci USA 2000;97:13949-54.
6. Shan Q, Haddrill JL, Lynch JW. Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J Biol Chem 2001;276:12556-64.
7. Ros-Moreno RM, Moreno-Guzman MJ, Jimenez-Gonzalez A, et al. Interaction of ivermectin with gamma-aminobutyric acid receptors in Trichinella spiralis muscle larvae. Parasitol Res 1999;85:320-3.
8. Shoop WL. Structure and activity of avermectins and milbemycins in animal health. Vet Parasitol 1995;59:139-56.
9. Bredal WP. Deaths associated with ivermectin for scabies. Lancet 1997;350:216.
10. Seward RL. Reactions in dogs given ivermectin. J Am Vet Med Assoc 1983;183(5):493.
11. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144-5.
12. Coyne P, Addiss D. Deaths associated with ivermectin for scabies. Lancet 1997;350:215-6.
13. Alexander NDE, Bockarie MJ, Kastens WA, et al. Absence of ivermectin-associated excess deaths. Trans R Soc Trop Med Hyg 1998;92:342.
14. Currie B, Huffam S, O'Brien D, et al. Ivermectin for scabies. Lancet 1997;350(9090):1551.
15. Dean M. Lymphatic filariasis: the quest to eliminate a 4000-year old disease. Hollis (NH): Puritan Press, Hollis Publishing Company; 2001.
16. Reintjes R, Hoek C. Deaths associated with ivermectin for scabies. Lancet 1997;350:215.
17. Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for the treatment of strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996;55:477-81.
18. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
19. Smith AJ, van Helvoort A, van Meer G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000;275:23530-9.
20. Brieger WR, Awedoba AK, Eneanya CI, et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 1998;3:951-61.
21. Brown KR, Neu DC. Ivermectin-clinical trials and treatment schedules in onchocerciasis. Acta Leiden 1990;59:169-75.
22. Newell ED. Effect of mass treatments with ivermectin, with only partial compliance, on the prevalence and intensity of O. volvulus infection in adults and in untreated 4 and 5 year old children in Burundi. Trop Med Int Health 1997;2:912-6.
23. Ngoumou P, Essomba RO, Godin C. Ivermectin-based onchocerciasis control in Cameroon. World Health Forum 1996;17:25-8.
24. Toma H, Sato Y, Shiroma Y, et al. Comparative studies on the efficacy of three antihelminthics on treatment of human strongyloidiasis in Okinawa, Japan. Southeast Asian J Trop Med Public Health 2000;31:147-51.
25. Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169:1076-9.
26. Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994;73:256-63.
27. Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol 2001;18:63-5.
28. Youssef MY, Sadaka HA, Eissa MM, et al. Topical application of ivermectin for human ectoparasites. Am J Trop Med Hyg. 1995;53:652-3.
29. Leppard B, Naburi AE. The use of ivermectin in controlling an outbreak of scabies in a prison. Br J Dermatol 2000;143:520-3.
30. Conti Diaz IA, Amaro J. Treatment of human scabies with oral ivermectin. Rev Inst Med Trop Sao Paulo 1999;41:259-61.
31. Madan V, Jaskiran K, Gupta U, et al. Oral ivermectin in scabies patients: a comparison with 1% topical lindane lotion. J Dermatol 2001;28:481-4.
32. Usha V, Gopalakrishnan-Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000;42:236-40.
33. Alberici F, Pagani L, Ratti G, et al. Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies. Br J Dermatol 2000;142:969-72.
34. Huffam SA, Currie BJ. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis 1998;2:152-4.
35. Meinking TL, Taplin D, Hermida JL, et al. The treatment of scabies with ivermectin. N Engl J Med 1995;333:26-30.
36. Burkhart CG, Burkhart CN. Optimal treatment for scabies remains undetermined. J Am Acad Dermatol 2001;45:637-8.
37. Haas N, Henz BM, Ohlendorf D. Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol 2001;40:599-600.
38. Elgart ML. A risk-benefit assessment of agents used in the treatment of scabies. Drug Safety 1996;14:386-93.
39. Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg 2000;94:92-6.
40. Downs AM, Stafford KA, Hunt LP, et al. Widespread insecticide resistance in head lice to the over-the-counter pediculocides in England, and the emergence of carbaryl resistance. Br J Dermatol 2002;146:88-93.
41. Meinking TL, Serrano L, Hard B, et al. Comparative in vitro pediculocidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol 2002;138:220-4.
42. Glaziou P, Nyguyen LN, Moulia-Pelat JP, et al. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol 1994;45:253-4.
43. Das PK, Ramaiah KD, Vanamail P, et al. Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India. Trans R Soc Trop Med Hyg 2001;95:336-41.
44. El Haouri M, Erragragui Y, Sbai M, et al. [Cutaneous filariasis Loa Loa: 26 Moroccan cases of importation]. Ann Dermatol Venereol 2001;128:899-902.
45. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of Bancroftian filariasis. Trans R Soc Trop Med Hyg 1998;1:94-7.
46. Nguyen NL, Moulia-Pelat JP, Cartel JL. Control of Bacroftian filariasis in an endemic area of Polynesia by ivermectin 400micrograms/kg. Trans R Soc Trop Med Hyg 1996;90:689-91.
47. Bouchaud O, Houze S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis 2000;31:493-8.
48. Caumes E, Datry A, Paris L, et al. Efficacy of ivermectin in the therapy of cutaneous larva migrans. Arch Dermatol 1992;128:994-5.
49. Caumes E, Carriere J, Datry A, et al. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg 1993;49:641-4.
50. Caumes E. Treatment of cutaneous larva migrans. Clin Infect Dis 2000;30:811-4.
51. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999;41(5 Pt 1):775-7.
52. Jelenek T, Nothdurft HD, Rieder N, et al. Cutaneous myiasis: review of 13 cases in travelers returning from tropical countries. Int J Dermatol 1995;34:624-6.